Opendata, web and dolomites

ONCORNET2.0 SIGNED

ONCOgenic Receptor Network of Excellence and Training 2.0

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ONCORNET2.0 project word cloud

Explore the words cloud of the ONCORNET2.0 project. It provides you a very rough idea of what is the project "ONCORNET2.0" about.

leads    tumours    incorporation    play    crispr    interdisciplinary    delivered    transferable    demand    rarely    burden    learning    technological    multidisciplinary    biological    gpcrs    protein    extensive    photochemistry    receptors    therapeutic    ackr3    pis    first    gender    cxcr4    exposure    scientific    cellular    blended    successful    drug    understand    modulation    functions    builds    cell    multiple    stage    cas    leveraging    coupled    chemokine    moving    intersectoral    talented    proteins    poorly    deaths    incorporate    training    responsible    druggable    strategies    skills    excellence    regulating    breaking    etn    oncornet    balanced    esrs    integral    em    generation    fast    yield    biology    critical    cancer    skill    groups    network    15    nanobodies    20    gpcr    team    discovery    cryo    oncornet2    oncogenic    industries    academically    surface    fundamental    health    progression    ground    microscopy    integrates    scientists    successfully    commercialisation    mechanisms    young    expressed    brings   

Project "ONCORNET2.0" data sheet

The following table provides information about the project.

Coordinator
STICHTING VU 

Organization address
address: DE BOELELAAN 1105
city: AMSTERDAM
postcode: 1081 HV
website: www.vu.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 4˙099˙781 €
 EC max contribution 4˙099˙781 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2019
 Funding Scheme MSCA-ITN-ETN
 Starting year 2020
 Duration (year-month-day) from 2020-02-01   to  2024-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STICHTING VU NL (AMSTERDAM) coordinator 1˙062˙479.00
2    THE UNIVERSITY OF NOTTINGHAM UK (NOTTINGHAM) participant 606˙345.00
3    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) participant 549˙604.00
4    UNIVERSITY OF GLASGOW UK (GLASGOW) participant 303˙172.00
5    INTERAX BIOTECH AG CH (VILLINGEN) participant 281˙276.00
6    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 274˙802.00
7    QVQ HOLDING BV NL (UTRECHT) participant 265˙619.00
8    MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (MDC) DE (BERLIN) participant 252˙788.00
9    Universitätsklinikum Jena DE (Jena) participant 252˙788.00
10    UNIVERSIDAD AUTONOMA DE MADRID ES (MADRID) participant 250˙904.00

Map

 Project objective

Cancer is a major health burden responsible for 20% of European deaths. There is a critical need to understand its fundamental biological mechanisms. G protein-coupled receptors (GPCRs) are cell surface proteins which play an important role in regulating cellular functions integral to cancer biology and, as highly druggable proteins, oncogenic GPCRs are important therapeutic targets. ONCORNET2.0 builds on the success of ONCORNET (Oncogenic GPCR Network of Excellence and Training), a first-in-kind ETN in GPCR drug discovery that has successfully delivered scientific advance and training to talented early stage researchers (ESRs). ONCORNET2.0 will incorporate recent scientific and technological advances to understand and target two oncogenic GPCRs; the chemokine receptors CXCR4 and ACKR3. These are highly expressed in multiple tumours but their role in cancer progression remains poorly understood. We will develop new strategies for CXCR4/ACKR3 modulation (photochemistry, nanobodies) and investigate their effects on oncogenic responses, to yield key new knowledge and potential leads for drug development and commercialisation. ONCORNET2.0 will bring together the leading GPCR research groups in Europe and 15 ESRs. By leveraging on the success and experience of ONCORNET and recent ground-breaking advances in the field of GPCRs (e.g. cryo-EM, CRISPR-Cas, advanced microscopy), ONCORNET2.0 brings a young, gender-balanced team of PIs to target oncogenic GPCRs. The consortium will offer an extensive multidisciplinary training programme for ESRs ensuring their successful incorporation in today’s fast-moving drug development programmes. This programme integrates both research and transferable skill sets through blended learning. Our aim is that, through training these ESRs with interdisciplinary and intersectoral exposure, we will develop the next generation of scientists with skills that are in high demand by the drug development industries but rarely offered academically.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCORNET2.0" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ONCORNET2.0" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

PARACAT (2019)

Paramagnetic Species in Catalysis Research. A Unified Approach Towards Heterogeneous, Homogeneous and Enzyme Catalysis

Read More  

ARCH (2019)

AGE-RELATED CHANGES IN HEMATOPOIESIS

Read More  

GROWTH (2019)

Research and Training in Early Life Nutrition to Prevent Disease

Read More